IntelliPharmaCeutics International (TSXV:IPCI) Short-Term Debt : C$2.93 Mil (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Short-Term Debt?

IntelliPharmaCeutics International's Short-Term Debt for the quarter that ended in Aug. 2023 was C$2.93 Mil.

IntelliPharmaCeutics International's quarterly Short-Term Debt increased from Feb. 2023 (C$2.91 Mil) to May. 2023 (C$2.92 Mil) and increased from May. 2023 (C$2.92 Mil) to Aug. 2023 (C$2.93 Mil).

IntelliPharmaCeutics International's annual Short-Term Debt declined from Nov. 2020 (C$2.56 Mil) to Nov. 2021 (C$2.41 Mil) but then increased from Nov. 2021 (C$2.41 Mil) to Nov. 2022 (C$2.91 Mil).

IntelliPharmaCeutics International Short-Term Debt Historical Data

The historical data trend for IntelliPharmaCeutics International's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Short-Term Debt Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Short-Term Debt

Get a 7-Day Free Trial

2.36

2.52

2.56

2.41

2.91

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Short-Term Debt	Get a 7-Day Free Trial															2.53	2.91	2.91	2.92	2.93

IntelliPharmaCeutics International Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

IntelliPharmaCeutics International Short-Term Debt Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines